{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T03:45:15Z","timestamp":1776743115294,"version":"3.51.2"},"reference-count":37,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.clml.2025.12.005","type":"journal-article","created":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T06:29:03Z","timestamp":1766125743000},"page":"e492-e501.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cytogenetic Testing in Newly Diagnosed Multiple Myeloma: Real World Evidence on Clinical Features and Adverse Outcomes for High Risk Groups"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7108-7615","authenticated-orcid":false,"given":"Ghassan","family":"Zammar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bradley","family":"Augustson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Moore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6115-5394","authenticated-orcid":false,"given":"Cameron","family":"Wellard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elham","family":"Ashrafi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hasib","family":"Sidiqi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth J.C.","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5660-7685","authenticated-orcid":false,"given":"Dejan","family":"Radeski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alannah","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krystal","family":"Bergin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. Joy","family":"Ho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9477-2794","authenticated-orcid":false,"given":"Tracy","family":"King","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hang","family":"Quach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8537-1198","authenticated-orcid":false,"given":"Peter","family":"Mollee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajeev","family":"Rajagopal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Rosengarten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7527-2340","authenticated-orcid":false,"given":"Erica","family":"Wood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zoe","family":"McQuilten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Spencer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"26","key":"10.1016\/j.clml.2025.12.005_bib0001","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised international staging system for multiple myeloma: a report from International Myeloma Working Group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J Clin Oncol"},{"issue":"34","key":"10.1016\/j.clml.2025.12.005_bib0002","doi-asserted-by":"crossref","first-page":"4032","DOI":"10.1200\/JCO.22.02228","article-title":"Second revision of the International Staging System (R2-ISS) for Overall Survival in Multiple myeloma: a European Myeloma Network (EMN) report within the HARMONY Project [published correction appears in J Clin Oncol","volume":"40","author":"D'Agostino","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2025.12.005_bib0003","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41408-022-00611-x","article-title":"A simple additive staging system for newly diagnosed multiple myeloma","volume":"12","author":"Abdallah","year":"2022","journal-title":"Blood Cancer J"},{"issue":"24","key":"10.1016\/j.clml.2025.12.005_bib0004","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1200\/JCO-24-01893","article-title":"International Myeloma Society\/International Myeloma Working Group Consensus recommendations on the definition of high-risk multiple Myeloma","volume":"43","author":"Avet-Loiseau","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2025.12.005_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2024.101168","article-title":"Chromosomal defects in multiple myeloma","volume":"64","author":"Clarke","year":"2024","journal-title":"Blood Rev"},{"issue":"9","key":"10.1016\/j.clml.2025.12.005_bib0006","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1002\/ajh.27422","article-title":"Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management","volume":"99","author":"Rajkumar","year":"2024","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2025.12.005_bib0007","series-title":"Clinical practice guideline multiple myeloma","author":"Quach","year":"2022"},{"issue":"1","key":"10.1016\/j.clml.2025.12.005_bib0008","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1182\/hematology.2021000229","article-title":"High-risk multiple myeloma: how to treat at diagnosis and relapse?","volume":"2021","author":"Mateos","year":"2021","journal-title":"Hematology"},{"key":"10.1016\/j.clml.2025.12.005_bib0009","doi-asserted-by":"crossref","unstructured":"Avet-Loiseau H., Attal M., Moreau P., et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du My\u00e9lome. Blood. 2007;109(8):3489-95. doi: 10.1182\/blood-2006-08-040410.","DOI":"10.1182\/blood-2006-08-040410"},{"issue":"11","key":"10.1016\/j.clml.2025.12.005_bib0010","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.clml.2015.07.641","article-title":"Outcomes among high-risk and standard-risk multiple myeloma patients treated with high-dose chemotherapy and autologous hematopoietic stem-cell transplantation","volume":"15","author":"Kazmi","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"2","key":"10.1016\/j.clml.2025.12.005_bib0011","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/leu.2011.204","article-title":"A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial","volume":"26","author":"Boyd","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2025.12.005_bib0012","doi-asserted-by":"crossref","DOI":"10.1200\/JCO-24-01253","article-title":"Co-occurrence of cytogenetic abnormalities and high-risk disease in newly diagnosed and relapsed\/refractory multiple myeloma","author":"Kaiser","year":"2025","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clml.2025.12.005_bib0013","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/s12874-016-0250-z","article-title":"Design and development of the Australian and New Zealand (ANZ) myeloma and related diseases registry","volume":"16","author":"Bergin","year":"2016","journal-title":"BMC Med Res Methodol"},{"issue":"9","key":"10.1016\/j.clml.2025.12.005_bib0014","doi-asserted-by":"crossref","first-page":"e600","DOI":"10.1038\/bcj.2017.83","article-title":"Prognostic implications of abnormalities of chromosome 13 and the presence of multiple cytogenetic high-risk abnormalities in newly diagnosed multiple myeloma","volume":"7","author":"Binder","year":"2017","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2025.12.005_bib0015","doi-asserted-by":"crossref","first-page":"5991","DOI":"10.1038\/s41598-020-62885-0","article-title":"Concepts of double hit and triple hit disease in multiple myeloma, entity and prognostic significance","volume":"10","author":"Baysal","year":"2020","journal-title":"Sci Rep"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.12.005_bib0016","doi-asserted-by":"crossref","first-page":"6953","DOI":"10.1182\/blood-2024-206098","article-title":"Outcomes of double-hit and single high risk cytogenetic newly diagnosed myeloma in transplant eligible patients","volume":"144","author":"Rahman","year":"2024","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.clml.2025.12.005_bib0017","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41408-020-00348-5","article-title":"Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment response","volume":"10","author":"Abdallah","year":"2020","journal-title":"Blood Cancer J"},{"issue":"2","key":"10.1016\/j.clml.2025.12.005_bib0018","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/leu.2013.258","article-title":"Relationship between initial clinical presentation and the molecular cytogenetic classification of myeloma","volume":"28","author":"Greenberg","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2025.12.005_bib0019","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1186\/s12885-024-13124-6","article-title":"Clinical and immunological characteristics of high-risk double-hit multiple myeloma","volume":"24","author":"Shang","year":"2024","journal-title":"BMC Cancer"},{"issue":"12","key":"10.1016\/j.clml.2025.12.005_bib0020","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.1080\/10428194.2021.1948032","article-title":"At least two high-risk cytogenetic abnormalities indicate the inferior outcomes for newly diagnosed multiple myeloma patients: a real-world study in China","volume":"62","author":"Shen","year":"2021","journal-title":"Leuk Lymph"},{"issue":"8","key":"10.1016\/j.clml.2025.12.005_bib0021","doi-asserted-by":"crossref","first-page":"e685","DOI":"10.1016\/j.clml.2022.03.005","article-title":"Presentation and impact of double and triple hit cytogenetics in patients with multiple myeloma in the real world","volume":"22","author":"Singh","year":"2022","journal-title":"Clin Lymph Myeloma Leuk"},{"key":"10.1016\/j.clml.2025.12.005_bib0022","doi-asserted-by":"crossref","unstructured":"Gonz\u00e1lez-Calle, V., Rodriguez-Otero, P., Calasanz, M.J., et al. (2024). High-risk cytogenetic abnormalities in multiple myeloma: PETHEMA-GEM experience. HemaSphere, 8(12), e70031. https:\/\/doi.org\/10.1002\/hem3.70031.","DOI":"10.1002\/hem3.70031"},{"issue":"Suppl 2","key":"10.1016\/j.clml.2025.12.005_bib0023","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1016\/S2152-2650(21)02126-1","article-title":"OAB-052: Impact of chromosome 1 abnormalities on newly diagnosed multiple myeloma treated with proteasome inhibitor, immunomodulatory drug, and dexamethasone: analysis from the ENDURANCE ECOG-ACRIN E1A11 trial","volume":"21","author":"Kapoor","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"10.1016\/j.clml.2025.12.005_bib0024","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41408-024-01088-6","article-title":"Daratumumab in transplant-eligible patients with newly diagnosed multiple myeloma: final analysis of clinically relevant subgroups in GRIFFIN","volume":"14","author":"Chari","year":"2024","journal-title":"Blood Cancer J"},{"issue":"10","key":"10.1016\/j.clml.2025.12.005_bib0025","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1016\/S1470-2045(21)00428-9","volume":"22","author":"Moreau","year":"2021","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.clml.2025.12.005_bib0026","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJMoa2312054","article-title":"PERSEUS trial investigators. Daratumumab, Bortezomib, Lenalidomide, and dexamethasone for multiple myeloma","volume":"390","author":"Sonneveld","year":"2024","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.clml.2025.12.005_bib0027","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S1470-2045(22)00693-3","article-title":"Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial","volume":"24","author":"Mina","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2025.12.005_bib0028","doi-asserted-by":"crossref","unstructured":"MF. Kaiser, R Phillip, A Hall, et al. Ultra high-risk multiple myeloma patients with multi-hit tumours and SKY92 high risk signature are at increased risk of early relapse even when treated with extended intensified induction and consolidation - results from the Optimum\/Muknine trial. 142, Supplement 1, 2023. https:\/\/doi.org\/10.1182\/blood-2023-177896","DOI":"10.1182\/blood-2023-177896"},{"issue":"1","key":"10.1016\/j.clml.2025.12.005_bib0029","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/s41408-025-01286-w","article-title":"Guidelines for the testing and reporting of cytogenetic results for risk stratification of multiple myeloma: a report of the Cancer Genomics Consortium Plasma Cell Neoplasm Working Group","volume":"15","author":"Lu","year":"2025","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1016\/j.clml.2025.12.005_bib0030","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1186\/s12885-024-13309-z","article-title":"The impact of high-risk cytogenetic abnormalities in extramedullary multiple myeloma in the era of novel agents: insights from a multicenter study","volume":"24","author":"Liang","year":"2024","journal-title":"BMC Cancer"},{"issue":"6","key":"10.1016\/j.clml.2025.12.005_bib0031","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1007\/s12185-022-03353-5","article-title":"Multiple myeloma with high-risk cytogenetics and its treatment approach","volume":"115","author":"Hanamura","year":"2022","journal-title":"Int J Hematol"},{"issue":"3","key":"10.1016\/j.clml.2025.12.005_bib0032","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK_433520","article-title":"Navigating high-risk and ultrahigh-risk multiple myeloma: challenges and emerging strategies","volume":"44","author":"Rees","year":"2024","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"17","key":"10.1016\/j.clml.2025.12.005_bib0033","doi-asserted-by":"crossref","first-page":"4082","DOI":"10.3390\/cancers14174082","article-title":"Multiple myeloma therapy: emerging trends and challenges","volume":"14","author":"Dima","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"14","key":"10.1016\/j.clml.2025.12.005_bib0034","doi-asserted-by":"crossref","first-page":"7470","DOI":"10.3390\/ijms22147470","article-title":"Next-generation biomarkers in multiple myeloma: understanding the molecular basis for potential use in diagnosis and prognosis","volume":"22","author":"Soliman","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1016\/j.clml.2025.12.005_bib0035","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.clml.2024.11.002","article-title":"Presence of 1q21 gain and amplification may be associated with poorer outcomes in Daratumumab-treated multiple myeloma patients","volume":"25","author":"Lim","year":"2025","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"11","key":"10.1016\/j.clml.2025.12.005_bib0036","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.3324\/haematol.2010.023697","article-title":"Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma","volume":"95","author":"Lod\u00e9","year":"2010","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.clml.2025.12.005_bib0037","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1182\/blood.2020008346","article-title":"del(17p) without TP53 mutation confers a poor prognosis in intensively treated newly diagnosed patients with multiple myeloma","volume":"137","author":"Corre","year":"2021","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025043009?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025043009?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T03:15:47Z","timestamp":1776741347000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265025043009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S2152265025043009"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.12.005","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cytogenetic Testing in Newly Diagnosed Multiple Myeloma: Real World Evidence on Clinical Features and Adverse Outcomes for High Risk Groups","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.12.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}